Table 3.

T cell responses against HPV16 and 18 peptides in patients with HPV-associated LGTN

Donor	Disease	HPV type	Spots per 105 cells
			16 E6a	16 E7	18 E6	18 E7	PPP
CTRL003	CIN3	16, 18	—	—	—	—	≥200
CTRL005	CIN3	16	—	—	—	—	≥200
CTRL006	CIN3	16	49	—	—	43	111
CTRL008	CIN3	33, 39 + 58	—	—	—	—	51
CTRL009	CIN3	NT	—	—	62	—	≥200
CTRL010	CIN3	18	62	27	—	—	≥200
CTRL012	CIN3	16, 39	—	—	—	—	≥200
CTRL014	VAIN3	HR (not 16/18)	—	—	—	—	≥200
CTRL015	VIN3	NT	—	—	—	—	139
CTRL016	CIN3	NT	—	—	30	—	147
CTRL020	CIN3	16	26	—	—	—	≥200
VAC001	VIN3	16	—	—	—	—	≥200
VAC002	VIN3	16	—	—	—	—	≥200
VAC003	CIN3	16	79	—	34	54	≥200
VAC004	VAIN3	16	IS	IS	IS	IS	IS
VAC005	VIN3	NT	57	—	—	—	≥200
VAC006	CIN3	52	28	50	—	—	106
VAC007	CIN3	16	HB	HB	HB	HB	HB
VAC008	CIN3	16, 51	—	—	—	—	151
VAC009	CIN3	31	—	—	—	—	≥200
VAC010	CIN3	18	63	—	—	36	≥200
VAC011	CIN3	16, 31	—	22	—	—	≥200

NT denotes not tested, VAIN3 denotes vaginal intraepithelial neoplasia, — denotes no significant response above background, IS denotes insufficient sample and HB denotes non-interpretable results due to high background in several assays.